Zhejiang Lanyu Digital Technology
301585
BBK Test Systems
301598
MEIZHIGAO
834765
Youkeshu Technology
300209
Hangzhou Raycloud Technology Co.,Ltd
688365
CN Stock MarketDetailed Quotes
688105 Nanjing Vazyme Biotech
- 23.64
- +0.10+0.42%
Market Closed Dec 20 15:00 CST
9.51BMarket Cap400.68P/E (TTM)
23.80High23.21Low12.18KlotVolume23.43Open23.54Pre Close28.67MTurnover0.30%Turnover RatioLossP/E (Static)402.13MShares32.7552wk High2.40P/B9.51BFloat Cap16.8252wk Low28.25Limit Up402.13MShs Float128.82Historical High18.83Limit Down2.51%Amplitude16.82Historical Low0.13Dividend TTM23.53Avg Price5.56KlotAsk0.55%Div YieldTTM100Lot Size5.95KlotBid
Nanjing Vazyme Biotech Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 13.42%985.91M | 13.70%649.27M | -0.21%301.57M | -63.97%1.29B | -62.29%869.3M | -64.74%571.04M | -69.02%302.19M | 90.99%3.57B | 78.87%2.31B | 96.20%1.62B |
| Operating revenue | 13.42%985.91M | 13.70%649.27M | -0.21%301.57M | -63.97%1.29B | -62.29%869.3M | -64.74%571.04M | -69.02%302.19M | 90.99%3.57B | 78.87%2.31B | 96.20%1.62B |
| Total operating cost | 3.09%1.02B | -0.14%665.65M | -9.55%317.25M | -39.78%1.4B | -30.49%989.19M | -25.39%666.55M | -23.75%350.73M | 113.63%2.33B | 120.38%1.42B | 140.06%893.35M |
| Operating cost | 15.17%291.03M | 20.03%189.95M | -7.84%87.26M | -66.45%372.56M | -59.64%252.69M | -62.23%158.25M | -61.53%94.68M | 216.52%1.11B | 265.58%626.12M | 284.99%419.02M |
| Operating tax surcharges | 144.43%7.72M | 128.49%6.16M | 132.43%2.07M | -87.46%2.42M | -68.44%3.16M | -61.26%2.7M | -75.98%890.6K | 173.57%19.28M | 77.90%10.01M | 83.91%6.96M |
| Operating expense | 2.36%337.26M | -4.15%217.66M | -0.14%103.03M | -9.52%472.69M | -4.63%329.5M | 11.57%227.08M | 14.75%103.18M | 63.52%522.4M | 71.46%345.48M | 96.46%203.53M |
| Administration expense | -6.11%162.43M | -6.49%108.52M | -18.73%53.87M | -20.36%236.19M | -4.48%173M | 3.43%116.06M | 35.07%66.29M | 64.92%296.57M | 55.24%181.12M | 61.68%112.21M |
| Financial expense | 143.69%6.79M | 109.32%878.24K | -67.02%259.3K | -28.90%-19.33M | -61.88%-15.53M | -76.43%-9.42M | 1,934.82%786.17K | -582.82%-15M | -442.29%-9.59M | -368.17%-5.34M |
| -Interest expense (Financial expense) | -14.63%23.5M | 2.12%15.58M | 77.83%8.96M | 181.08%35.07M | 263.82%27.52M | 212.07%15.26M | 41.98%5.04M | 222.90%12.48M | 191.26%7.57M | 238.84%4.89M |
| -Interest Income (Financial expense) | 54.80%-17.52M | 14.87%-16.31M | -47.11%-9.5M | -124.80%-52.36M | -136.61%-38.76M | -77.98%-19.16M | 0.61%-6.46M | -634.62%-23.29M | -2,926.24%-16.38M | -2,986.99%-10.77M |
| Research and development | -12.94%214.51M | -17.11%142.48M | -16.66%70.76M | -14.51%338.62M | -8.71%246.38M | 9.50%171.89M | 19.32%84.91M | 71.98%396.11M | 82.53%269.9M | 85.73%156.97M |
| Credit Impairment Loss | -155.13%-11.49M | -138.73%-8.19M | -113.33%-1.64M | 104.79%4.5M | 189.86%20.84M | 250.54%21.15M | 207.37%12.28M | -631.16%-94.05M | -77.00%-23.19M | -271.78%-14.05M |
| Asset Impairment Loss | 77.89%-18.22M | 84.53%-11.79M | 85.65%-8.7M | 73.06%-142.32M | 2.08%-82.41M | -48.34%-76.25M | -198.29%-60.66M | -1,250.09%-528.23M | -184.06%-84.16M | -186.66%-51.41M |
| Other net revenue | ||||||||||
| Fair value change income | 29.25%42.81M | 6.44%27.74M | 18.27%16.6M | -6.23%43.04M | 41.35%33.12M | 158.93%26.06M | 56.28%14.03M | 687.35%45.9M | 259.53%23.43M | 172.68%10.06M |
| Invest income | -55.45%3.04M | -30.68%1.69M | -74.39%529.19K | -81.29%7.88M | -82.97%6.83M | -90.38%2.43M | -77.84%2.07M | 75.68%42.12M | 167.72%40.08M | 183.62%25.31M |
| -Including: Investment income associates | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -41.70%-2.15M | ---2.31M | -579.35%-1.8M |
| Asset deal income | -129.77%-1.64M | -264.79%-1.13M | 678.81%324.61K | 2,726.13%5.67M | 1,078.83%5.5M | 20,319.31%683.78K | -229.55%-56.08K | -2,083.81%-215.72K | 1,536.88%466.54K | -105.42%-3.38K |
| Other revenue | -79.03%8.12M | -65.67%5.01M | -80.34%2.76M | 663.71%98.2M | 391.15%38.73M | 114.03%14.61M | 337.69%14.05M | -15.96%12.86M | 94.03%7.89M | 81.66%6.82M |
| Operating profit | 88.50%-11.19M | 97.15%-3.05M | 91.31%-5.8M | -113.96%-100.18M | -111.49%-97.29M | -115.19%-106.83M | -113.23%-66.83M | -6.96%717.49M | 35.29%846.49M | 56.89%703.1M |
| Add:Non operating Income | -44.23%550.68K | -69.43%328.87K | -66.48%93.69K | -21.35%1.08M | 15.52%987.47K | 59.70%1.08M | -22.24%279.53K | 494.97%1.37M | 485.49%854.82K | 361.45%673.73K |
| Less:Non operating expense | -120.29%-2.42M | -307.15%-2.49M | -332.01%-3.35M | -84.83%16.61M | 1,330.93%11.94M | 106.62%1.2M | 256.14%1.44M | 1,481.24%109.47M | -64.32%834.51K | 22.71%581.79K |
| Total profit | 92.41%-8.22M | 99.79%-229.91K | 96.52%-2.36M | -118.99%-115.71M | -112.79%-108.25M | -115.21%-106.95M | -113.46%-67.99M | -20.28%609.39M | 35.76%846.51M | 57.03%703.19M |
| Less:Income tax cost | 17.36%-25.23M | 37.77%-15.53M | 56.85%-7.24M | -369.80%-42.85M | -131.47%-30.53M | -127.97%-24.97M | -122.76%-16.78M | -81.56%15.88M | 32.36%97.02M | 59.49%89.25M |
| Net profit | 121.89%17.01M | 118.67%15.3M | 109.52%4.88M | -112.28%-72.86M | -110.37%-77.72M | -113.35%-81.99M | -111.87%-51.21M | -12.50%593.51M | 36.22%749.5M | 56.67%613.94M |
| Net profit from continuing operation | 121.89%17.01M | 118.67%15.3M | 109.52%4.88M | -112.28%-72.86M | -110.37%-77.72M | -113.35%-81.99M | -111.87%-51.21M | -12.50%593.51M | 36.22%749.5M | 56.67%613.94M |
| Less:Minority Profit | 13.71%-1.14M | 4.57%-854.49K | 41.72%-341.1K | -157.99%-1.91M | -458.41%-1.33M | -42,844,266.03%-895.45K | -31,636,538.38%-585.28K | -923,357,750.00%-738.69K | ---237.63K | ---2.09 |
| Net profit of parent company owners | 123.77%18.16M | 119.93%16.16M | 110.30%5.22M | -111.94%-70.96M | -110.19%-76.39M | -113.21%-81.09M | -111.74%-50.62M | -12.39%594.25M | 36.26%749.74M | 56.67%613.94M |
| Earning per share | ||||||||||
| Basic earning per share | 126.32%0.05 | 120.00%0.04 | 107.69%0.01 | -112.08%-0.18 | -110.16%-0.19 | -113.07%-0.2 | -112.04%-0.13 | -20.32%1.49 | 22.22%1.87 | 40.37%1.53 |
| Diluted earning per share | 126.32%0.05 | 120.00%0.04 | 107.69%0.01 | -112.08%-0.18 | -110.16%-0.19 | -113.07%-0.2 | -112.04%-0.13 | -20.32%1.49 | 22.22%1.87 | 40.37%1.53 |
| Other composite income | 136.49%1.14M | 79.08%-703.82K | -116.69%-239.32K | -1.72M | -3.11M | -3.36M | 1.43M | |||
| Other composite income of parent company owners | 136.48%1.14M | 79.07%-703.87K | -116.69%-239.32K | ---1.72M | ---3.11M | ---3.36M | --1.43M | ---- | ---- | ---- |
| Other composite income of minority owners | 445.83%51.01 | 266.06%48.09 | 14.74%-1.62 | ---1.97 | ---14.75 | ---28.96 | ---1.9 | ---- | ---- | ---- |
| Total composite income | 122.45%18.15M | 117.11%14.6M | 109.31%4.64M | -112.57%-74.58M | -110.78%-80.83M | -113.90%-85.35M | -111.54%-49.77M | -12.50%593.51M | 36.22%749.5M | 56.67%613.94M |
| Total composite income of parent company owners | 124.27%19.29M | 118.30%15.46M | 110.12%4.98M | -112.23%-72.68M | -110.60%-79.5M | -113.76%-84.46M | -111.40%-49.19M | -12.39%594.25M | 36.26%749.74M | 56.67%613.94M |
| Total composite income of minority owners | 13.72%-1.14M | 4.58%-854.44K | 41.72%-341.11K | -157.99%-1.91M | -458.42%-1.33M | -42,845,651.67%-895.48K | -31,636,641.08%-585.28K | -923,357,750.00%-738.69K | ---237.63K | ---2.09 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
